Top 10 trends in life sciences manufacturing location strategy

The landscape of U.S. life sciences and MedTech manufacturing is undergoing a profound structural shift. While the "lab-office" boom of the early 2020s has cooled into a period of inventory digestion, the manufacturing sector—encompassing Biopharma (Good Manufacturing Practice or GMP facilities) and MedTech production—is entering a high-stakes era of expansion. For commercial real estate (CRE) stakeholders, the strategy is no longer just about "being near the bench"; it is about the "path to the patient" and the "resiliency of the line."

As we navigate 2026, location strategy is being redefined by domestic policy, labor scarcities, and the specific technical requirements of next-generation modalities. Here are the top 10 trends shaping the U.S. life sciences and MedTech manufacturing footprint.
 

1. The Rise of "Production Clusters" Over Research Hubs

Traditional hubs like Kendall Square or South San Francisco remain the R&D gold standard, but manufacturing is migrating to "production-ready" secondary markets.

The Geographic Shift: Regions like Raleigh-Durham (Research Triangle), Greater Philadelphia, and Columbus are winning large-scale manufacturing projects due to lower land costs, better utility infrastructure, and favorable tax environments. The trend is clear: R&D stays in the Tier 1 cities, but the "steel in the ground" for commercial-scale production is moving to markets where $1,000 per square foot construction costs aren't the baseline.

2. "Reshoring" Driven by Federal Incentives

Geopolitical volatility and the lessons of the pandemic have made supply chain sovereignty a boardroom priority. Federal initiatives, including the CHIPS and Science Act (impacting MedTech electronics) and provisions in the Inflation Reduction Act (IRA), are incentivizing domestic production. We are seeing a "flight to the U.S." for critical API (Active Pharmaceutical Ingredient) and medical device component manufacturing, moving away from over-reliance on offshore facilities in Asia.

3. The Power Play: Infrastructure and Utility Redundancy

For manufacturing, the "real estate" is often secondary to the "grid." Location strategy now prioritizes sites with massive power capacity and water/wastewater redundancy.

Infrastructure as the Primary Differentiator: As biomanufacturing processes become more energy-intensive, sites that can offer dual-feed power or proximity to renewable energy microgrids are fetching premiums. In markets like Frederick, MD, or Fishers, IN, the availability of "plug-and-play" utility infrastructure is the primary differentiator between a viable site and a "passed" opportunity.

4. Labor-Centric Site Selection

The technical talent gap is the industry's greatest bottleneck. Location strategy is now hyper-focused on "technical college corridors." Companies are selecting sites specifically located near community colleges with specialized bioprocessing or precision machining programs. The goal is to build a "cradle-to-career" pipeline, as seen with recent investments in North Carolina where Genentech and Fujifilm Diosynth have aligned with local education systems to ensure a steady flow of GMP-ready operators.

5. Transition to "Small-Scale, Localized" MedTech Facilities

In the MedTech sector, the trend is moving away from massive, monolithic plants toward smaller, more agile regional facilities.

Agility Over Scale: This allows for faster response times to local hospital systems and minimizes shipping costs for large, heavy medical equipment. This shift favors infill industrial locations—repurposing older warehouse stock into high-tech assembly and sterilization centers near major logistics hubs like Memphis or Louisville.

6. The "IRA Effect" on Modality Real Estate

The Inflation Reduction Act's pricing negotiations distinguish between small-molecule drugs (9 years of price protection) and large-molecule biologics (13 years). This is significantly impacting location strategy. We are seeing a surge in demand for Biologics-focused GMP space (which requires more complex, specialized build-outs) while small-molecule manufacturing investment becomes more scrutinized. Real estate developers must now understand the molecular pipeline of their tenants to assess long-term lease stability.

7. Sustainability as a Lease Requirement

ESG (Environmental, Social, and Governance) is no longer a "nice-to-have" in the life sciences sector. Global pharma giants are mandating that their manufacturing footprints meet specific carbon-neutral targets. Location strategy now includes an audit of a site's "Green Credentials"—ranging from LEED Gold certification to the carbon footprint of the local power grid. Sites in regions with high percentages of nuclear or hydroelectric power are becoming increasingly attractive to ESG-conscious tenants.

8. The Expansion of CDMO Footprints

As biotech firms lean out their internal operations, the reliance on Contract Development and Manufacturing Organizations (CDMOs) has hit record levels. CDMOs are currently the most active occupiers of manufacturing real estate. They require flexible, multi-tenant "shell and core" buildings that can be quickly adapted for different clients. This creates a new asset class for CRE investors: the "CDMO-anchored industrial park."

9. AI and "Lights-Out" Manufacturing

The integration of AI and robotics in manufacturing is reducing the headcount-per-square-foot requirements while increasing the power and data-cooling needs.

Technology Enabling Geographic Flexibility: "Lights-out" manufacturing (fully automated production) allows facilities to be located in areas with lower labor availability but higher power reliability. This technology is enabling the revitalization of older industrial zones in the Midwest (the "Bio-Belt"), where land is plentiful and data connectivity is strong.

10. Speculative Manufacturing: The Next CRE Frontier

For years, "speculative" was a dirty word in life sciences manufacturing due to the extreme costs. However, in 2025, we are seeing the rise of "Spec-to-Suit" models. Developers are building "warm shells" with enhanced floor loads, 30-foot clear heights, and pre-permitted utility capacities. This reduces a tenant's speed-to-market by 12–18 months, a critical advantage when a drug or device receives FDA (Food and Drug Administration) approval and needs to scale immediately.

The intersection of life sciences and commercial real estate has matured. The industry has moved past the "build it and they will come" phase into a disciplined, data-driven approach to site selection. For the CRE professional, success in this sector now requires a deep understanding of bioprocessing requirements, federal policy, and the shifting geography of the American workforce.

Ready to navigate the evolving life sciences manufacturing landscape? Contact JLL's Life Sciences team to discuss how these trends impact your location strategy and real estate portfolio.